Fount of Information

InvivoGen社 Learn how InvivoGen supports AI drug screening

この製品に関するご意見・ご照会・お問合せはこちら

 

Conjugatable_PRR_Ligands_1.png

Artificial Intelligence in Drug Discovery

 

Technologies that utilize artificial intelligence (AI) have emerged to improve precision and speed up the time-consuming drug discovery phases. Many AI companies are thus partnering with pharma or biotech companies to help computationally screen through compound library and identify potential drug candidates. Here are a few examples of recent collaboration between AI companies and pharmas:

 

Learn_how_InvivoGen_supports_AI_drug_screening_2.png

PRR Screening Service

 

Understanding the needs in AI-driven drug discovery, InvivoGen offers a high quality immunomodulatory compound screening service that can aid AI players in screening the compound library. Through validating the biological activities of compounds with cell-based assays, AI systems could narrow down the candidate choices and identify better molecules. Using our engineered HEK293 cells, compounds of interest can be tested for a panel of PRR ligands, including TLR, NOD1/2, RIG-I/ MDA-5, Dectin-1, Mincle and STING.

Screening Service Level 1

Learn_how_InvivoGen_supports_AI_drug_screening_3.png

  • Compound Profiling
    Single dose testing on a set of PRRs

Screening Service Level 2

Learn_how_InvivoGen_supports_AI_drug_screening_4.png

  • Compound Dose Response
    Dose response on one or several PRRs

SARS-CoV-2 Spike Pseudotyping Vectors

 
InvivoGen offers a collection of plasmids specifically designed for pseudotyping lentiviral particles with the full-length SARS-CoV-2 Spike (S) protein. These plasmids can also be used for screening of SARS-CoV-2 inhibitors including small molecules, monoclonal antibodies, or convalescent plasma.

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。